Key Highlights

  • Shares rose 1.92% in today's session to around $31.72 following the Journal publication.
  • The Phase 3 RAPIDe-3 study showed a median time to symptom relief of 1.28 hours and complete resolution in 11.95 hours.
  • The study met its primary endpoint and all 11 secondary endpoints with high statistical significance.
  • An FDA decision on the drug is expected by a target action date in April 2027.

Rare Disease Data Reaches a High-Profile Medical Journal

Pharvaris (NASDAQ:PHVS) shares rose in today's session after the company announced that results from its Phase 3 RAPIDe-3 study were published in The Lancet, one of the most widely cited medical journals in the world. The study evaluated deucrictibant, an oral treatment for sudden attacks of hereditary angioedema, a rare condition that causes painful swelling episodes.

Pharvaris is a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists aimed at bradykinin-mediated conditions, with hereditary angioedema as its lead target indication.

Fast Symptom Relief Across Patient Subgroups

The RAPIDe-3 study met its primary endpoint and all 11 secondary endpoints with high statistical significance. Patients treated with deucrictibant saw a median time to onset of symptom relief of 1.28 hours and complete symptom resolution in 11.95 hours, with most attacks controlled using a single capsule.

Results were consistent across patient subgroups defined by age, geography, disease type, and attack severity, including non-severe episodes affecting the throat, reinforcing the drug's potential as a reliable on-demand option.

Late-Stage Pipeline With Regulatory Decisions on the Horizon

Pharvaris carries a market Capitalization near $2.22 billion. The company is developing two formulations of deucrictibant, an immediate-release capsule for on-demand treatment and an extended-release tablet aimed at preventing attacks before they start, giving it a potential presence across both treatment and prevention.

Outlook: Regulatory Decisions Expected in 2027

With a New Drug Application under review by the FDA and a target action date in April 2027, alongside a parallel review by European regulators, investors will likely watch for regulatory updates as the next major catalysts for the stock.